Non-pharmacological treatments for COVID-19: current status and consensus

Pereira, Adriano Alves; Andrade, Adriano de Oliveira; Palis, Angélica de Andrade; Cabral, Ariana Moura; Barreto, Cassiana Gabriela Lima; Souza, Daniel Baldoíno de; Silva, Fernanda de Paula; Santos, Fernando Pasquini; Silva, Gabriella Lelis; Guimarães, José Flávio Viana; Araújo, Laureane Almeida Santiago de; Nóbrega, Lígia Reis; Mendes, Luanne Cardoso; Brandão, Mariana; Milagre, Selma Terezinha; Gonçalves, Verônica de Lima; Morales, Victor Hugo de Freitas; Lima, Viviane da Conceição

doi:10.1007/s42600-020-00116-1

Cited by 6 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-pharmacological therapies have been the cornerstone in the care of COVID-19 due to a lack of appropriate medicines. These include preventative measures such as social distancing, hand washing, using face masks, and reducing public gatherings, among others [34]. Non-pharmacological treatments also include supportive therapies like oxygen therapy for those patients presenting with more severe symptoms and requiring hospitalization [27,35].…”

Section: Current Management Of Covid-19mentioning

confidence: 99%

“…Supportive treatments are another category of non-pharmacological management used for COVID-19 patients. The most common are oxygen therapy, the prone position, and nitric oxide inhalation [61].…”

Section: Non-pharmacological Managementmentioning

confidence: 99%

“…Non-invasive ventilation is an assisted respiratory support technique which is used to avoid the difficulties faced during intubation [64]. It is usually approved for patients at early stages of COVID-19 infection and also for individuals with milder immunosuppressive and cardiovascular complications but it only delays the invasive ventilation [65,61].…”

Section: Non-pharmacological Managementmentioning

confidence: 99%

See 2 more Smart Citations

Role of Nanotechnology in Diagnosing, Safeguarding, and Treating COVID-19

Rohini M. de Silvaa,

Kenneth Hulugallaa,

Panchali Ranasinghe

et al. 2023

SQU Journal for Science

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) is arguably the worst health crisis the world has faced in the 21st century, and the World Health Organization declared this a “public health emergency of international concern” during the beginning of the pandemic and continued for a significant period of time. Considering the public health risk and the delay in introducing a suitable medical intervention to eradicate this virus, many reserachers embarked on different technologies to develop a cure. Nanotechnology has emerged as a promising weapon in the fight against COVID-19 and other similar viral diseases. The unique qualities of nanomaterials make them excellent for a variety of applications, including the development of low-cost, real-time diagnostic systems, reusable personal protective equipment, and innovative carriers for biological cargo such as mRNA in vaccines and CRISPR/Cas9 in gene editing. In this review the current available pharmacological and non-pharmacological options that are being used around the world against COVID-19 are compared with their nanotechnological counterparts. Here, we also elaborate the advantages of currently available nanotechnology-based diagnostics, protective equipment, vaccines and therapeutics and discuss future directions and steps that should be taken to translate these technologies into a clinical setting to combat the COVID-19 pandemic.

show abstract

Section: Current Management Of Covid-19mentioning

confidence: 99%

Section: Non-pharmacological Managementmentioning

confidence: 99%

Section: Non-pharmacological Managementmentioning

confidence: 99%

See 1 more Smart Citation

Role of Nanotechnology in Diagnosing, Safeguarding, and Treating COVID-19

Rohini M. de Silvaa,

Kenneth Hulugallaa,

Panchali Ranasinghe

et al. 2023

SQU Journal for Science

View full text Add to dashboard Cite

show abstract

“…Spike protein can activate the cells via the interaction with the toll-like receptors (TLRs) resulting in the pro-inflammatory cytokines production ( 14 , 15 ). Currently, no effective therapy is available for the management of long-COVID symptoms, while only common drugs have been prescribed for supportive therapies ( 16 ). Therefore, our attention has been drawn to the search for novel plant and active compounds with potential preventive therapeutic effects that could reduce lung inflammation and relieve long-COVID symptoms.…”

Section: Introductionmentioning

confidence: 99%

Luteolin-rich fraction from Perilla frutescens seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe multi-systemic inflammation as a result of COVID-19 can persevere long after the initial symptoms of the illness have subsided. These effects are referred to as Long-COVID. Our research focused on the contribution of the Spike protein S1 subunit of SARS-CoV-2 (Spike S1) on the lung inflammation mediated by NLRP3 inflammasome machinery and the cytokine releases, interleukin 6 (IL-6), IL-1beta, and IL-18, in lung epithelial cells. This study has attempted to identify the naturally- occurring agents that act against inflammation-related long-COVID. The seed meal of Perilla frutescens (P. frutescens), which contains two major dietary polyphenols (rosmarinic acid and luteolin), has been reported to exhibit anti-inflammation activities. Therefore, we have established the ethyl acetate fraction of P. frutescens seed meal (PFEA) and determined its anti-inflammatory effects on Spike S1 exposure in A549 lung cells.MethodsPFEA was established using solvent-partitioned extraction. Rosmarinic acid (Ra) and luteolin (Lu) in PFEA were identified using the HPLC technique. The inhibitory effects of PFEA and its active compounds against Spike S1-induced inflammatory response in A549 cells were determined by RT-PCR and ELISA. The mechanistic study of anti-inflammatory properties of PFEA and Lu were determined using western blot technique.ResultsPFEA was found to contain Ra (388.70 ± 11.12 mg/g extract) and Lu (248.82 ± 12.34 mg/g extract) as its major polyphenols. Accordingly, A549 lung cells were pre-treated with PFEA (12.5-100 μg/mL) and its two major compounds (2.5-20 μg/mL) prior to the Spike S1 exposure at 100 ng/mL. PFEA dose-dependently exhibited anti-inflammatory properties upon Spike S1-exposed A549 cells through IL-6, IL-1β, IL-18, and NLRP3 gene suppressions, as well as IL-6, IL-1β, and IL-18 cytokine releases with statistical significance (p < 0.05). Importantly, Lu possesses superior anti-inflammatory properties when compared with Ra (p < 0.01). Mechanistically, PFEA and Lu effectively attenuated a Spike S1-induced inflammatory response through downregulation of the JAK1/STAT3-inflammasome-dependent inflammatory pathway as evidenced by the downregulation of NLRP3, ASC, and cleaved-caspase-1 of the NLRP3 inflammasome components and by modulating the phosphorylation of JAK1 and STAT3 proteins (p < 0.05).ConclusionThe findings suggested that luteolin and PFEA can modulate the signaling cascades that regulate Spike S1-induced lung inflammation during the incidence of Long-COVID. Consequently, luteolin and P. frutescens may be introduced as potential candidates in the preventive therapeutic strategy for inflammation-related post-acute sequelae of COVID-19.

show abstract

“…The physical, mental, psychological and economic effects of the COVID-19 pandemic have resulted in a humanitarian crisis of unprecedented levels. Several non-pharmacological interventions have been implemented to break the chain of community transmission 1 ; however, these preventive methods are not sustainable for a long time. COVID-19 vaccination is now the most crucial preventive measure towards control of the COVID-19 pandemic.…”

Section: Introductionmentioning

confidence: 99%